--- title: "NeuroPace (NPCE) stock listing, news and investor profile" url: "https://aibio.space/companies/neuropace/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NeuroPace Inc (NASDAQ: NPCE), United States. Listing facts, related biotech companies and news on aibio.space." --- NPCE NeuroPace Inc NASDAQ · United States # NeuroPace (NPCE) news NeuroPace Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NPCE, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest NeuroPace news We have not published a story on NeuroPace yet. When there is news, it will appear here. ## NeuroPace at a glance - **Ticker**: NPCE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $51.7 million ### Related companies - [LFTD PARTNERS INC.](https://aibio.space/companies/lftd-partners/) OTC: LIFD - [IM Cannabis](https://aibio.space/companies/im-cannabis/) NASDAQ: IMCC - [BIOMERICA INC](https://aibio.space/companies/biomerica/) NASDAQ: BMRA - [National Vision Holdings](https://aibio.space/companies/national-vision/) NASDAQ: EYE - [WEST PHARMACEUTICAL SERVICES INC](https://aibio.space/companies/west-pharmaceutical-services/) NYSE: WST - [ZIMMER BIOMET HOLDINGS, INC.](https://aibio.space/companies/zimmer-biomet/) NYSE: ZBH - [ORTHOPEDIATRICS CORP](https://aibio.space/companies/orthopediatrics/) NASDAQ: KIDS - [Aclarion](https://aibio.space/companies/aclarion/) NASDAQ: ACON ### Also on NASDAQ - [VERACYTE, INC.](https://aibio.space/companies/veracyte/) VCYT - [Biogen](https://aibio.space/companies/biogen/) BIIB - [Insight Molecular Diagnostics](https://aibio.space/companies/insight-molecular-diagnostics/) IMDX - [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) KPTI - [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) CAPR - [LivaNova](https://aibio.space/companies/livanova/) LIVN ## NeuroPace annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$100.0 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | [$79.9 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | | Research and development | [$27.9 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | [$23.7 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | | Net income (loss) | [-$21.5 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | [-$27.1 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | | Cash from operations | [-$11.0 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | [-$17.9 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | | Cash and equivalents | [$21.7 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000030/) | [$13.4 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | | Short-term investments | [$39.4 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000030/) | [$39.3 million](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.5 million, plus short-term investments of $39.2 million, $51.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NeuroPace What is the ticker symbol of NeuroPace? NeuroPace Inc trades under the ticker NPCE on NASDAQ. Where is NeuroPace listed? NeuroPace Inc is listed on NASDAQ. Which country or territory is NeuroPace listed under? Our directory records NeuroPace Inc under United States. Does aibio.space cover NeuroPace? aibio.space lists NeuroPace Inc among 2,820 public biotech companies and publishes its news here as stories appear. What was NeuroPace's revenue last year? $100.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is NeuroPace profitable? NeuroPace Inc reported a net loss of $21.5 million for the fiscal year ended Dec 31, 2025, and used $11.0 million of cash in operations, per its annual report to the SEC. How much does NeuroPace spend on research and development? $27.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NeuroPace have? $51.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: NeuroPace Members talk about NeuroPace (NPCE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NPCE on TradingView](https://www.tradingview.com/symbols/NASDAQ-NPCE/). ## Listing details NeuroPace Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NPCE, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NeuroPace Inc - **Ticker**: NPCE - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/neuropace/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NeuroPace (NPCE) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/neuropace/